Baharivand Nader, Zarghami Nosratollah, Panahi Farid, Dokht Ghafari M Yazdan, Mahdavi Fard Ali, Mohajeri Abbas
Department of Ophthalmology, Nikookari Eye Hospital, Tabriz, Iran.
Clin Ophthalmol. 2012;6:185-91. doi: 10.2147/OPTH.S27423. Epub 2012 Jan 26.
Diabetic retinopathy is a serious microvascular disorder of the retina. Vascular endothelial growth factor (VEGF) expression, induced by high glucose levels and hypoxia, is a main feature in retinopathy. The aim of this study was to evaluate the relationship between vitreous and serum VEGF levels and control of diabetes and microalbuminuria in patients with proliferative diabetic retinopathy.
Sixty-five patients were enrolled in this case-control study, comprising 30 patients with proliferative diabetic retinopathy (cases) and 35 patients with nonproliferative diabetic retinopathy (controls). The vitreous VEGF level was compared with the serum VEGF level in both groups. Glycosylated hemoglobin (HbA(1c)), microalbuminuria, serum creatinine, and stage of nephropathy and retinopathy were also measured in patients with proliferative diabetic retinopathy, and the relationship between these parameters and serum and vitreous VEGF levels was investigated.
Mean vitreous and serum VEGF levels were significantly higher in cases compared with controls (P = 0.001, P = 0.011, respectively). There was also a significant correlation between vitreous and serum VEGF levels (P = 0.012, r = 0.453). VEGF levels in patients with well controlled blood glucose (P = 0.039), on drug treatment (P = 0.045) and at an early stage of nephropathy (P = 0.042) were significantly lower. There was a significant correlation between VEGF and albumin to creatinine ratio (P = 0.017, r = 0.432).
Serum and vitreous VEGF levels was significantly lower in patients on oral therapy, in those with well controlled glycemia, and in those with early-stage retinopathy. Administration of anti-VEGF had a good effect in reducing the progression of proliferative diabetic retinopathy.
糖尿病视网膜病变是一种严重的视网膜微血管疾病。高血糖水平和缺氧诱导的血管内皮生长因子(VEGF)表达是视网膜病变的主要特征。本研究的目的是评估增殖性糖尿病视网膜病变患者玻璃体和血清VEGF水平与糖尿病控制及微量白蛋白尿之间的关系。
65例患者纳入本病例对照研究,其中30例增殖性糖尿病视网膜病变患者(病例组)和35例非增殖性糖尿病视网膜病变患者(对照组)。比较两组的玻璃体VEGF水平和血清VEGF水平。对增殖性糖尿病视网膜病变患者还测量了糖化血红蛋白(HbA1c)、微量白蛋白尿、血清肌酐以及肾病和视网膜病变分期,并研究这些参数与血清和玻璃体VEGF水平之间的关系。
病例组的平均玻璃体和血清VEGF水平显著高于对照组(分别为P = 0.001,P = 0.011)。玻璃体和血清VEGF水平之间也存在显著相关性(P = 0.012,r = 0.453)。血糖控制良好(P = 0.039)、接受药物治疗(P = 0.045)和处于肾病早期(P = 0.042)的患者VEGF水平显著较低。VEGF与白蛋白肌酐比值之间存在显著相关性(P = 0.017,r = 0.432)。
口服治疗患者、血糖控制良好患者以及早期视网膜病变患者的血清和玻璃体VEGF水平显著较低。抗VEGF治疗在减少增殖性糖尿病视网膜病变进展方面有良好效果。